Last reviewed · How we verify
NCT05679518
Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches
NA trial testing ConquerFear intervention in Advanced or Metastatic Cancer in 261 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 261 |
| Start date | 20 December 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 4 locations across Hong Kong |
Drugs / interventions tested
- ConquerFear intervention
- CALM intervention
- Basic Cancer Care
Conditions studied
- Advanced or Metastatic Cancer — all drugs for Advanced or Metastatic Cancer →
- Fear of Cancer Progression — all drugs for Fear of Cancer Progression →
- Metacognition-based Intervention — all drugs for Metacognition-based Intervention →
- Supportive-expressive Based Intervention — all drugs for Supportive-expressive Based Intervention →
Sponsor
The University of Hong Kong
Who can join
18 and older, any sex, with Advanced or Metastatic Cancer or Fear of Cancer Progression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study aims to conduct a randomized controlled trial to assess the effect of CALM intervention and ConquerFear intervention on fear of cancer progression among Chinese patients diagnosed with advanced cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05679518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05679518 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing